Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPC1001 vs Monotherapy in Essential Hypertension
NCT06212648Phase 2Completed
- Sponsor
- Shinpoong Pharma
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of candesartan + amlodipine + indapamide in essential hypertension, sponsored by Shinpoong Pharma. Started Mar 2022; status: completed.
02
Drugs
candesartan + amlodipine + indapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06212648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212648.